Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

May 2018

Prior Authorization Criteria Updated for Xgeva


Harvard Pilgrim has updated our prior authorization criteria for our commercial members for the medication Xgeva, which is used to protect the bones of patients with multiple myeloma and in patients with bone metastases from solid tumors.

For the use of Xgeva to treat bone metastases from prostate cancer, Harvard Pilgrim’s criteria no longer require that the patient has castration-recurrent prostate cancer. Coverage for Xgeva will continue to require prior authorization.

As a reminder, CVS Health–NovoLogix oversees our prior authorization program for medical drugs to optimize treatment outcomes and promote the safe and cost-effective use of these medications. To request authorization for Xgeva, please contact CVS Health–NovoLogix via phone (844-387-1435) or fax (844-851-0882).

For complete information, please refer to our new Xgeva Medical Review Criteria and the associated prior authorization request form.

    Email this article to a colleague   


    Network Matters Archives

    Download printer-friendly version

    HPHCURRENT EVENTS

    Sign Up for a Webinar on Our Genetic Testing Program

    CLINICIAN CORNER

    Decreasing Preventable ED Visits and Hospital Readmissions

    Coverage of Scanning Computerized Ophthalmic Diagnostic Imaging (SCODI)

    Prior Authorization Required for Brineura

    Prior Authorization Criteria Updated for Xgeva

    Mental Health Month and Alternative Health Benefits

    OFFICE ASSISTANT

    Reminder: Report Condition and Value Codes on Institutional Claims

    Update to Reimbursement of Codes With PC/TC Indicator of 3

    Reimbursement of 3D Rendering of Imaging Studies

    Correct Usage of Modifiers LT, RT, and 50

    PUBLICATION INFORMATION

    Eric H. Schultz,
    President and Chief Executive Officer

    Robert Farias,
    Senior Vice President, Corporate Network Strategy

    Annmarie Dadoly,
    Editor

    Joseph O'Riordan,
    Writer

    Kristin Edmonston,
    Production Coordinator